Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of EDP-938 with Cyclosporine and Prednisone
NCT03750383Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelicapavir in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of EDP-938 up to 21 days and Area Under the Plasma Concentration-Time Curve of EDP-938 up to 21 days. Started Nov 2018; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03750383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750383.